Update on community-acquired pneumonia

References

• Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159(21): 2562–72
   PubMedGoogle Scholar
• Stahl JE, Barza M, Desjardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community- acquired pneumonia. Arch Intern Med 1999; 159(21): 2576–80
   Google Scholar
• Mandell LA, Niederman MS. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. The Canadian Community-Acquired Pneumonia Consensus Conference Group. Can J Infect Dis 1993; 4: 25–8
   PubMedGoogle Scholar
• Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 148(5): 1418–26
   PubMedGoogle Scholar
• Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31(2): 383–421
   PubMedGoogle Scholar
• Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998; 26(4): 811–38
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31(2): 347–82
   PubMed Web of Science ®Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, et al; Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37(11): 1405–33
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163(7): 1730–54
   PubMed Web of Science ®Google Scholar
• Holmes KV. SARS-associated coronavirus. N Engl J Med 2003: 348(20): 1948–51
   PubMed Web of Science ®Google Scholar
• Stockton J, Stephenson I, Fleming D, et al. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis 2002; 8(9): 897–901
   PubMed Web of Science ®Google Scholar
• Zetola N, Francis JS, Nuermberger EL, et al. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005; 5(5): 275–86
   PubMed Web of Science ®Google Scholar
• Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278(23): 2080–4
   PubMed Web of Science ®Google Scholar
• Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community- acquired pneumonia. Arch Intern Med 2004; 164(6): 637–44
   PubMedGoogle Scholar
• Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161(15): 1837–42
   PubMedGoogle Scholar
• Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36(4): 389–95
   PubMed Web of Science ®Google Scholar
• Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978–1997. Am J Med 1999; 107(1 A): 34–43S
   Google Scholar
• Yu VL, Chiou CC, Feldman C, et al; International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37(2): 230–7
   PubMed Web of Science ®Google Scholar
• O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17(12): 828–33
   PubMed Web of Science ®Google Scholar
• Hoepelman IM, Mollers MJ, van Schie MH, et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxicillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 1997; 9(3): 141–6
   Google Scholar
• Tellier G, Isakov T, Petermann W, et al. Efficacy and safety of telithro-mycin (800 mg once daily) for 5 or 7 days vs clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia. (Abstr L-373). In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Sep 27–30, 2002. Washington, DC: American Society for Microbiology, 2002: 346
   Google Scholar
• Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37(6): 752–60 [Erratum, Clin Infect Dis 2003; 37(8): 1147]
   PubMed Web of Science ®Google Scholar
• Aventis. Unpublished data on file.
   Google Scholar
• Ely EW, Laterre PF, Angus DC, et al; PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31(1): 12–9
   PubMed Web of Science ®Google Scholar
• Abraham E, Reinhart K, Opal S, et al; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290(2): 238–47
   PubMed Web of Science ®Google Scholar